The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.
Introduction
In Canada, stroke is the leading cause of adult neurological disability, with over 400,000 Canadians living with its effects, and it ranks as the third leading cause of death.
1 Stroke costs the Canadian economy more than $3.6 billion a year in physician services, hospital costs, lost wages, and decreased productivity. 2 The impact of stroke can be seen even among persons who have sustained seemingly minor strokes or transient ischemic attacks (TIA). Canadian data indicate that even individuals free of post-stroke complications in the short term are at increased risk for cardiovascular events over the long term. 3 Therefore, the opportunity to reduce the risk of recurrent strokes through aggressive vascular risk factor reduction efforts represent a significant opportunity to lower the total stroke burden. The Canadian Stroke Best Practice Recommendations have been developed to provide up-to-date evidence-based guidelines for the prevention and management of stroke, to promote optimal recovery and reintegration for people who have experienced stroke (patients, families, and informal caregivers). The target audience for this set of guidelines encompasses all health care professionals involved in the care of people with stroke across the continuum, and for those at increased risk of stroke. The goals of developing these recommendations and disseminating and promoting their implementation are to reduce practice variations in the care of stroke patients across geographic regions, reduce the gap between current knowledge and clinical practice, and to improve patient outcomes.
The 2017 update of the Canadian Stroke Best Practice Recommendations Secondary Prevention guidelines includes a summary of current evidencebased recommendations appropriate for use by health care professionals across all disciplines who provide care to patients following an ischemic stroke or transient ischemic attack. The focus of these recommendations is on the recurrent stroke risk reduction in patients who have experienced a stroke or transient ischemic attack. In some cases, this module may also guide health care providers for individuals at risk of a first stroke based on current health status and the presence of one or more vascular risk factors. However, only selected recommendations related to primary prevention are included.
Changes to secondary prevention of stroke recommendations in this update
The evidence for the topics addressed in this sixth edition has evolved in many areas. This module includes the development of a new set of core elements for delivering prevention services, which can be used to review, expand, and improve current stroke prevention services, regardless of setting. 4 With advances in imaging, the triage categories for estimating risk of recurrent stroke have been refined (Section 1). A new section has been added to address antithrombotic management in people with cervicocephalic artery dissection (Section 8). With the recent completion of the REDUCE 5 and CLOSE 6 trials, and long-term follow-up from the RESPECT trial, 7 the recommendations for people with patent foramen ovale have been updated (Section 9).
Sleep apnea is a recognized risk factor for stroke, and a condition that appears in some patients both before and following a stroke. However, the results from the recent SAVE trial 8 demonstrated that although treatment with continuous positive airway pressure (CPAP) for moderate-to-severe sleep apnea in patients with a history of coronary and cerebrovascular disease was associated with benefits, including reduced daytime sleepiness and improved healthrelated quality of life, the risks of recurrent stroke or major cardiovascular events were not reduced significantly. Accordingly, we have removed our previous recommendations for universal screening and treatment in stroke patients. Screening and treatment for sleep apnea should be performed as part of routine primary care based on the presence or absence of symptoms, as is currently done for patients without stroke. topic area were selected as were those who are considered leaders and experts in their field, having been involved in research on the topics addressed in this module. Persons with experience in the review and appraisal of research evidence and individuals (or family members of individuals) who had experienced a stroke were also included either as group members or external reviewers in the development process. The interprofessional writing group and external reviewers include stroke neurologists, nurses, family physicians, emergency department clinicians, epidemiologists, pharmacists, care coordinators, and health system planners. These experts work in a wide range of health care settings. This interprofessional approach ensured that the perspectives and nuances of all relevant health disciplines and care settings were considered in the development of the recommendations, and mitigated the risk of potential or real conflicts of interest from individual members.
A comprehensive systematic literature search was conducted to identify research evidence on the identification and management of persons following minor stroke or transient ischemic attack. The literature for this module was updated to September 2017. The writing group extensively reviewed and discussed the results and consensus was reached on the recommendation revisions, updated additions and deletions from the previous version. For a more detailed description of the methodology on development and dissemination please refer to the Canadian Stroke Best Practice Recommendations overview and methodology documentation available on the Canadian stroke best practices website at http:// www.strokebestpractices.ca/wp-content/uploads/2017/ 08/CSBPR2017_Overview_Methodology_ENG.pdf. 13 All recommendations are assigned a level of evidence ranging from A to C, according to the criteria defined in Table 1 . 13, 14 When developing and including ''C-Level'' recommendations, consensus was obtained within the writing group and validated through the internal and external review process. This level of evidence is used cautiously, and only when there is a lack of stronger evidence for topics considered important system drivers for stroke care. In some sections, additional information was identified as important to include, even though it did not meet the evidence criteria for a ''recommendation''. This information has been included as ''clinical considerations'' intended to provide additional guidance or clarity in the absence of evidence. 13 An additional category for Clinical Considerations has been added for the sixth edition. Included in this section are expert opinion statements in response to reasonable requests from a range of health care professionals who seek guidance and direction from the experts on specific clinical issues faced on a regular basis in the absence of any evidence on that topic.
Canadian Stroke Best Practice Recommendations: Secondary Prevention Guidelines, Update 2017
The following sections provide detailed updated recommendations associated with secondary prevention of stroke assessment and management practices, and do, on occasion address issues related to primary stroke prevention, although the focus of these recommendations is not primary prevention. Also, these recommendations pertain to patients with transient ischemic attack or ischemic stroke who are not immediate Secondary stroke prevention is an individually based clinical approach aimed at reducing the risk of recurrent stroke and other vascular events in individuals who have already experienced a stroke or transient ischemic attack.
1,2 Secondary prevention recommendations in this document are directed to those risk factors most relevant to stroke, including lifestyle (diet, sodium intake, exercise, weight, smoking, and alcohol intake), hypertension, dyslipidemia, previous stroke or transient ischemic attack, atrial fibrillation, and carotid stenosis. Secondary prevention recommendations can be addressed in a variety of settings-acute care, stroke prevention clinics, and community-based care settings. They pertain to patients initially seen in primary care, those who are treated in an emergency department and then discharged, and those who are hospitalized because of stroke or transient ischemic attack. Each section of these recommendations is supported by detailed evidence tables and a summary of the evidence, a rationale for the importance of the topic, system implications to facilitate timely and efficient implementation, key quality indicators for measuring performance and resources to support implementation and uptake for health care professionals and for patients. These are available at www.strokebestpractices.ca.
Section 1: Initial risk stratification and management of nondisabling stroke or TIA The goal of outpatient management of transient ischemic attack and nondisabling ischemic stroke is to rapidly identify cardiovascular risk factors, which may have precipitated the initial event, and to initiate treatments to reduce the risk of recurrent events. Historically, the 90-day risk of recurrent stroke following an index transient ischemic attack has been estimated to be relatively high, between 12% and 20%, 16, 17 with the greatest risk of recurrence within the first two days following initial symptom onset. However, the long-term risk of recurrent events over 5 years among persons with minor stroke or transient ischemic attack who did not experience any early complications has been recently shown to be over 5 times greater. 3 For patients with multiple risk factors, the 7-day risk of stroke following a transient ischemic attack can be as high as 36%. 18 With the recent adoption or expansion of the availability of rapid transient ischemic attack clinics, and urgent evaluation by stroke specialists, the risk of recurrent stroke has been reduced significantly. The increased use and availability of sensitive neuroimaging to identify minor events as well as increased use of antiplatelets, anticoagulants, antihypertensive agents, lipid-lowering agents, and carotid endarterectomy has been shown to significantly reduce the risk of major stroke after an initial minor event. 19 A recent study by the transient ischemic attack Registry.Org group reported updated rates that were less than half that expected from historical cohorts, which were attributed to better and faster implementation of stroke prevention strategies through rapidaccess transient ischemic attack clinics. Stroke recurrences at days 2, 7, 30, 90, and 365 were 1.5%, 2.1%, 2.8%, 3.7%, and 5.1%, respectively. 20 Similar risk reductions were demonstrated in the Early Use of Existing Preventive Strategies for Stroke (EXPRESS) study. 21 The 90-risk of recurrent stroke among patients who were referred to a dedicated transient ischemic attack clinic was 2.1% as compared with 10.3% for patients from an earlier time period, who did not have immediate access.
1.0 Patients with stroke or transient ischemic attack who present to an ambulatory setting (such as primary care) or a hospital should undergo clinical evaluation by a healthcare professional with expertise in stroke care to determine risk for recurrent stroke and initiate appropriate investigations and management strategies. 28 for women, no more than 10 drinks per week, with no more than 2 drinks per day most days and no more than 3 drinks on any single occasion; for men, no more than 15 drinks per week, with no more than 3 drinks per day most days and no more than 4 drinks on any single occasion [Evidence Level C].
Timing of initial assessment
Note: One standard drink is considered to be 13.6 g or 17.2 mL of ethanol, or approximately 44 mL of 80 proof (40%) spirits, 355 mL of 5% beer or 148 mL of 12% wine. factors, including 20% for diets low in fruits and vegetables, 13% for diets high in sodium, 11% for low levels of physical activity, 28% for a body mass index greater than 23.0, and 13% for tobacco use. These results are consistent with other reports. The recent INTERSTROKE 2 study 24 reported that among 10 risk factors, the odds of all stroke were 2.5 times higher among persons with a self-reported history of hypertension, 2 times higher among heavy alcohol consumers and over 1.5 times higher for tobacco smokers. The associated population attributable risk estimates were 34%, 5.8%, and 12%, respectively. Since rates of recurrent stroke and other vascular disorders are known to be significantly elevated during the first four years after hospitalization for first stroke, 25 and potentially modifiable risk factors represent approximately 90% of the population-attributable risk for stroke, 24 secondary prevention measures represent an important opportunity to reduce the risk of future stroke.
Section 3: Blood pressure and stroke prevention
Elevated blood pressure is the single most important risk factor for stroke, and is also regarded as the most important modifiable risk factor. Numerous population-based studies have found that elevated blood pressure is a significant risk factor for first and recurrent stroke. Systolic hypertension is estimated to account for about 64% of the stroke burden, globally, while In Canada, the contribution is lower, estimated at about 45%. 23 Results from the INTERSTROKE 2
Smoking cessation
Note: The term ''Smoking'' in these recommendations refers to tobacco and other inhaled substances. International Journal of Stroke, 13 (4) study suggested the odds of experiencing any stroke were 2.56 times higher among persons with selfreported hypertension and 3.7 times higher for hemorrhagic stroke. 24 The odds were even higher when the criteria for hypertension also included measured blood pressure in excess of 140/90 mm Hg. Using data from 1.25 million people, included in the CALIBER database Rapsomanki et al. 29 estimated the lifetime risk of ischemic stroke (from age of 30 years) in persons with hypertension to be 7.6% compared with 6.5% without hypertension, corresponding to loss of life of approximately a half a year due to ischemic stroke.
While the optimal target blood pressure to prevent a first or recurrent stroke has not been formally established, the current treatment recommendation is to attain a blood pressure of consistently lower than 140/90 mm Hg for people who have had a cerebrovascular event. There is a wealth of evidence from large clinical trials and meta-analyses that have been published over the past 30 years indicating that stroke risk is significantly reduced among at-risk persons when blood pressure is reduced and maintained within recommended levels, using a variety of antihypertensive agents, alone, or in combination with other agents. Using the results from 147 randomized controlled trials (RCTs), Law et al. 30 reported that a blood pressure treatment resulting in a reduction of 10 mm Hg systolic and 5 mm Hg diastolic was 
Clinical considerations
i. Children who have had a stroke, and their families, should be counseled to avoid hypotensive situations where they might drop their cerebral perfusion pressure and risk ischemia, such as dehydration especially with vomiting/diarrhea. associated with a 41% reduced risk of stroke. The results from a Cochrane review 31 suggested that among persons 60 years of age or greater, with moderate to severe hypertension treated primarily with firstline thiazide diuretic therapy for an average of 4.5 years, there was a significantly reduced risk of allcause mortality, and lower total cardiovascular morbidity and mortality.
Section 4: Lipid management
Given the well-documented causal relationship between dyslipidemia and the development of atherosclerosis, its appropriate management is important for both primary and secondary prevention of stroke. Current strategies emphasize the need to balance lifestyle factors modifications through behaviors change with pharmacological intervention, as required. Those who have already had an ischemic stroke or transient ischemic attack will benefit from treatment with a statin. While the superiority of the long-term use of a statin agent relative to a placebo for primary stroke prevention has been well-established in numerous large RCTs, there are fewer trials that have examined the additional benefit from higher (versus lower) statin doses. Results from the treating to new targets (TNT) trial 33 suggest that aggressive reduction of low-density lipoprotein (LDL) cholesterol, achieved through higher doses of a statin, are associated with greater benefit than more modest reductions. In this trial, the LDL cholesterol levels of participants with clinically evident coronary heart disease and baseline LDL-chol of <3.4 mmol/L, who received 80 mg atorvastatin for approximately 5 years were reduced from 2.6 to 2.0 mmol/L. The risk of fatal or nonfatal stroke or transient ischemic attack was subsequently reduced by 23% compared with person taking a 10-mg dose. The Cholesterol Treatment Trialists, 34 meta-analysis including the results of 14 statin trials showed a dose-dependent relative reduction in cardiovascular disease with LDL cholesterol lowering. Every 1.0 mmol/L reduction in LDL cholesterol was associated with a corresponding 20% to 25% reduction in cardiovascular disease mortality and nonfatal myocardial infarction. The risk of any stroke was reduced by 15% with statin therapy. Results from the recent FOURIER trial 35 highlight the benefit of more aggressive treatment, using additional agents when necessary, for patients with clinically evident atherosclerotic cardiovascular disease.
Section 5: Diabetes and stroke
In persons with diabetes, the risk of stroke, particularly ischemic stroke, is increased. The independent contribution of diabetes is difficult to determine, since many other risk factors for stroke, including hypertension, dyslipidemia, and atrial fibrillation, are more frequent in persons with diabetes. In addition to the traditional risk factors, those specifically associated with metabolic syndrome (insulin resistance, central obesity, impaired glucose tolerance and hyperinsulinemia), which are International Journal of Stroke, 13(4) common in diabetes, also contribute to the increased risk.
Consequently, in persons with diabetes, stroke outcomes are worse, and are associated with increased mortality, more residual neurologic and functional disability and longer hospital stays. Although tighter glycemic control along with other risk factor reduction strategies, including hypertension and hyperlipidemia, can collectively help to reduce stroke risk, aggressive glycemic control may not confer greater protection. In the glucose-lowering arm of the ACCORD Study, 37 the benefit of intensive therapy to reduce glycated hemoglobin (HbA1c) levels to reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors, was assessed. Patients with a median HbA1c level of 8.1% were randomly assigned to receive intensive therapy (targeting an HbA1c level <6.0%) or standard therapy (targeting a level from 7.0% to 7.9%). The trial was stopped early due to mortality trends suggesting an increased risk of death from any cause associated with intensive therapy. By 4 months, although mean HbA1c values had fallen to 6.7% in the intensive group compared with 7.5% in the control group, there was no reduction in the risk of nonfatal MI, nonfatal stroke or death from cardiovascular causes, associated with intensive glucose lowering. Patients in the intensive group required medical assistance for hypoglycemia more frequently and a greater proportion gained >10 kg. Results from the Veterans Affairs Diabetes Trial 38 also examined intensive glucose control in persons with poorly-controlled diabetes. While HbA1c values were significantly lower in the intensive glucose control group, after a median Refer to Section 3 for information on blood pressure management in an individual with stroke and diabetes; refer to Prevention of Stroke Section 4 for information on lipid management in an individual with stroke and diabetes. Note: For recommendations on the use of SGLT2 inhibitors, please refer to the current Diabetes Canada guidelines at www.diabetes.ca.
Clinical considerations (New for 2017)
i. The results from a recent trial, Pioglitazone after Ischemic Stroke or Transient Ischemic Attack 41 suggested that while there is a benefit of pioglitazone for stroke prevention in patients with positive insulin resistance, it is offset by the increased risk of fractures and bladder cancer. The decision to use this agent could be considered based on the specific risk profile for each patient. ii. More intensive glucose control (A1C 6.5%), may be considered in patients with a shorter duration of diabetes, no evidence of significant cardiovascular disease and longer life expectancy, provided this does not result in a significant increase in hypoglycemia (Diabetes Canada 2016).
duration of follow-up 5.9 years, there were no significant differences between groups on any of the primary or secondary outcomes, including the risk of stroke or transient ischemic attack. A meta-analysis including the results from six trials reported no significant reduction in the risk of all-cause mortality, stroke or cardiovascular mortality associated with intensive glycemic treatment; however, there was a significant 14% reduction in nonfatal myocardial infarction. 39 For patients with established cardiovascular disease whose blood glucose levels are not well controlled using standard therapy, the addition of a sodium glucose co-transpoter-2 inhibitor may reduce the risk of further events. In a trial using the SGLT-2 inhibitor, empagliflozin, after a median duration of follow-up of 3.1 years, the risks of cardiovascular mortality and allcause mortality were reduced by 38% and 32%, respectively. Collaborative (ATTC) meta-analysis, reported that the use of aspirin was associated with a 19% reduction in the risk of future ischemic stroke and a 23% reduction in stroke of unknown cause, without a significantly increased risk of hemorrhagic stroke. 42 The combination of clopidogrel plus aspirin has been associated with a 21% reduction in the risk of stroke and a 15% reduction in the risk of major vascular events, compared with aspirin alone; however, the risks of major bleeding and intracranial hemorrhage Note: These recommendations are applicable to ischemic stroke and transient ischemic attack.
6.1 All patients with ischemic stroke or transient ischemic attack should be prescribed antiplatelet therapy for secondary prevention of recurrent stroke unless there is an indication for anticoagulation [ 
i. At the present time, there is not enough evidence to guide management if a patient has a stroke while on a specific antiplatelet agent. In all cases of recurrent stroke while on antiplatelet therapy, all other vascular risk factors and stroke etiology should be reassessed and aggressively managed. ii. Expert opinion suggests that if a patient experiences a stroke while on ASA, it may be reasonable to consider switching to clopidogrel; if a patient experiences a stroke while on clopidogrel it may be reasonable to consider switching to combined acetylsalicylic acid (25 mg) and extended-release dipyridamole (200 mg).
Refer to Section 7 on Stroke and Atrial Fibrillation for additional recommendations on anticoagulant therapy.
International Journal of Stroke, 13 (4) were significantly increased. 43 A stratified analysis from the same study suggested that a significant increase in the risk of intracranial hemorrhage was only associated with long-term dual antiplatelet use. In contrast, the dual use of dipyridamole plus aspirin, was not associated with a significantly decreased risk of stroke recurrence compared with aspirin alone in a meta-analysis including the results of ESP-2, ESPRIT, and EARLY. 44 Section 7: Anticoagulation for individuals with stroke and atrial fibrillation Atrial fibrillation (AF), a common arrhythmia, is a significant risk factor for stroke. Detecting AF following a stroke or transient ischemic attack is important since, once identified, it can be effectively treated. Since most patients do not undergo prolonged screening, AF is often undetected and hence, the condition is generally under-diagnosed. The results from several RCTs have demonstrated that prolonged post-stroke ECG monitoring using wearable or insertable devices is effective for improving the detection of paroxysmal AF, with numbers needed to screen ranging from 8 to 14. [45] [46] [47] Longer monitoring durations have been associated with an increased probability of AF detection. In terms of treatment, new classes of drugs, such as direct thrombin inhibitors (e.g. dabigatran) and Factor Xa inhibitors (apixaban, edoxaban and rivaroxaban) have demonstrated benefits over previous standard therapy with warfarin. These direct-acting oral anticoagulants (DOACs) have been shown to be as effective, or superior to warfarin to reduce the risk of stroke or systemic embolism, with fewer side-effects. 48, 49 In addition to the recommendations below, practical guidance documents for DOAC therapy are available. 
Section 8: Management of extracranial carotid disease and intracranial atherosclerosis
Carotid endarterectomy (CEA) has been shown to prevent stroke recurrence in patients who have sustained a minor stroke or transient ischemic attack with ipsilateral high-grade carotid stenosis. Pooling the results from three major trails, the risk of any stroke or operative death at 5 years in patients with severe stenosis (70-99%) was significantly reduced among those in the CEA group (RR ¼ 0.53, 95% CI 0.42-0.67, p < 0.0001, NNT ¼ 6) compared with best medical management, with an associated absolute risk reduction of 16.0%. 52 For patients with moderate stenosis (50-69%) the risk was also reduced significantly (RR ¼ 0.77, 95% CI 0.63-0.94, p ¼ 0.001, NNT ¼ 22), while patients with mild stenosis did not benefit from treatment.
Perioperative death or stroke incidence was 7.0%. The greatest benefit of treatment was found in men, patients aged 75 years or over, and patients randomized within two weeks after their latest ischemic event. The use of CEA for asymptomatic carotid artery disease is more controversial. For selected patients with asymptomatic carotid stenosis, CEA reduces the risk of stroke from about 2% per year to about 1% per year. 53 Significant improvements have been made in the medical management of stroke risk factors during the previous 20 years, including the use of statins, antihypertensive agents, and antiplatelets or anticoagulants. These changes have reduced the frequency in which the procedure is undertaken.
Carotid-artery angioplasty with stenting (CAS) has emerged as an alternative to carotid endarterectomy in patients at high risk for complications for endarterectomy such as contralateral occlusion or severe coronary artery disease. The percutaneous approach also avoids the risks of general anesthesia and the local complications of neck hematoma, infection, cervical strain, and cranial nerve damage associated with endarterectomy and requires a shorter recovery period. In the SAMPRISS trial, aggressive medical management was found to be superior to intracranial stenting for patients with 70% to 99% stenosis of a major intracranial artery. Within 30 days of the procedure, the probability of the primary endpoint, stroke or death occurring, was significantly higher in the percutaneous transluminal angioplasty and stenting group (14.7% vs. 5.8%, p ¼ 0.0016). 54 Cephalocervical artery dissection, while relatively rare, is a common etiology of stroke in persons less than 45 years. To prevent recurrent events, treatment for three months with an antiplatelet or anticoagulant is recommended. Results from the CADISS trial 55 
Clinical considerations (new for 2017)
i. The optimal timing to start anticoagulant therapy after stroke has not been defined by clinical trial evidence, and should be based on individual benefit/risk assessment taking into account the clinical circumstances, infarct size, imaging appearances, age, comorbidities, and estimated stroke recurrence risk. ii. According to expert consensus, a general approach to the target timing of initiation of DOAC therapy post stroke may include:
1 day post-event or same day after a TIA, 3 days post stroke after a mild stroke, 6 days post stroke after a moderate stroke, and 12-14 days post stroke after a severe stroke. International Journal of Stroke, 13 (4) Note: These recommendations are applicable to ischemic stroke and transient ischemic attack. indicate that use of either agent is equally effective. In both groups, the frequency of stroke was low (2.4% for antiplatelets and 0.81% for anticoagulants), with no deaths in either group.
Section 9: Other cardiac issues in individuals with stroke
For many years, the role of percutaneous closure of a patent foramen ovale (PFO) for secondary stroke prevention was controversial for several reasons. While PFOs are known to be common in the general population (25%), 56 they are often incidental rather than pathogenic, and the results from previous RCTs were inconclusive. [57] [58] [59] In 2017, the publication of two new RCTs 5, 6 and long-term follow-up of an earlier one, 7 demonstrated that among carefully-selected patients, PFO closure was superior to medical therapy for prevention of stroke recurrence. The CLOSE trial 60 enrolled patients aged 16-60 years (mean age approximately 43 years) with a recent stroke and no identifiable cause other than a PFO, following detailed etiological work-up by a neurologist. The PFO had to be associated with either an atrial septal aneurysm (excursion >10 mm) or a large interatrial shunt (>30 microbubbles in the left atrium within three cardiac cycles after opacification of the right atrium). Mean follow-up was 5.3 AE 2.0 years. The stroke rate was 0 in the PFO-closure group vs. 6.0% in the antiplatelet-only group (mostly aspirin) (HR 0.03; 95% CI 0-0.26; p < 0.001; NNT ¼ 20 to prevent 1 stroke in 5 years; 95% CI: [17] [18] [19] [20] [21] [22] [23] [24] [25] . The rate of procedural complications was 5.9%, mostly consisting of atrial fibrillation (4.6% in the closure group vs. 0.9% in the antiplatelet group); most cases of atrial fibrillation were transient and did not recur during follow-up. The REDUCE trial 5 enrolled patients aged 18-59 years (mean age 45.2 years) with a PFO with a right-to-left shunt (spontaneous or during Valsalva maneuver), of whom 81% had moderate (6-25 microbubbles) or large (>25 microbubbles) interatrial shunts. Median followup was 3.2 years. The rate of ischemic stroke was 1.4% in the closure group vs. 5.4% in the antiplatelet-only group (HR 0.23; 95% CI 0.09-0.62; p ¼ 0.002; NNT ¼ 28 to prevent 1 stroke in 2 years). Serious device-related adverse events occurred in 1.4%, and 6.6% developed atrial fibrillation post-procedure (vs. 0.4% in the antiplatelet-only group); most cases of atrial fibrillation in the closure group were transient. The RESPECT trial has reported its extended followup results. 7 This trial enrolled patients aged 18-60 years (mean age 45.9 years) with a cryptogenic stroke and PFO. During a median follow-up of 5.9 years, the rate of recurrent ischemic stroke was 3.6% in the PFO closure group vs. 5.8% in the medical therapy group (antiplatelet therapy or warfarin) (HR 0.55; 95% CI 0.31-0.999; p ¼ 0.046; NNT ¼ 42 to prevent 1 stroke in 5 years). In subgroup analysis, the benefit of closure appeared to be driven by those with an atrial septal aneurysm or a ''substantial'' shunt size (grade 3).
In light of these new trial data, in addition to pooled analyses of earlier trials, 61, 62 there is now sufficient evidence to recommend PFO closure for very carefullyselected patients aged 60 years or younger with an unexplained embolic stroke event who are found to have a PFO and who do not require chronic anticoagulant therapy for another reason. PFO closure is not recommended for patients with stroke or TIA who are aged >60 years, and those at any age whose PFO is most likely incidental rather than causal for the index stroke event. In such circumstances, antiplatelet therapy alone is recommended for secondary stroke prevention, unless there is a separate evidence-based indication for anticoagulant therapy. PFO closure is also not recommended for primary stroke prevention. Patient counseling and shared decision-making, taking into account patient values and preferences, are important considerations. Patients considering PFO closure need to understand the benefits and risks of the procedure and the alternatives, and accept an up-front risk of procedural complications that is relatively small but potentially serious, including atrial fibrillation. Note: There is insufficient evidence at this time to make a recommendation regarding the use of DOACs in patients with arterial dissections.
iii. There is a lack of evidence regarding the use of anticoagulation in intracranial arterial dissection. Decisions may be based on individual clinical factors [Evidence Level C].
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The optimal management of patients with significant aortic arch atheroma is unclear. Typically, monotherapy with an antiplatelet agent or oral anticoagulation is used to prevent further events in patients with a prior ischemic stroke. Dual antiplatelet therapy with aspirin and clopidogrel was examined as a potential alternative to oral anticoagulation in the Aortic Arch Related Cerebral Hazard Trial (ARCH). 63 After a median of 3.4 years of follow-up, the risk of the primary outcome, a composite of cerebral infarction, myocardial infarction, peripheral embolism, vascular death, or intracranial hemorrhage was not significantly lower in the dual therapy group.
Similarly, the effectiveness of anticoagulation compared with antiplatelet therapy for stroke prevention in patients with heart failure in sinus rhythm remains unclear. In the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, 64 warfarin was associated with a significantly reduced risk of ischemic stroke (HR ¼ 0.52, 95% CI 0.33-0.82, p ¼ 0.005); however, the risks of major and minor hemorrhages were significantly increased. In sub group analysis, age was found to be an effect modifier, 65 whereby patients <60 years benefited from warfarin over aspirin, while for patients !60 years, the risk of the Note: These recommendations are applicable to ischemic stroke and transient ischemic attack. 66 While warfarin was associated with a decreased risk of nonfatal and total stroke compared with either antiplatelet agent, the risk of bleeding events was significantly higher among patients in the warfarin group.
Emerging trends in stroke prevention research
A key tenant to stroke prevention is knowing one's risk for stroke. A sizeable list of modifiable and nonmodifiable risk factors for stroke has been amassed. 67 Of these risk factors, family history, or genetic predisposition, is considered one of the most important risk factors. However, despite numerous epidemiological studies providing evidence for a genetic component to stroke, 68 the extent of this predisposition is largely unknown. 69 Moreover, genetic predisposition to stroke may act at several levels by: (1) contributing to standard risk factor that have a known genetic component such as hypertension or diabetes; (2) interacting with environmental factors; (3) contributing directly to an intermediate phenotype such as atherosclerosis; or (4) affecting latency to stroke, infarct size, or stroke outcome. 69 Clearly, the quest to identify the underlying molecular mechanisms contributing to stroke risk has been challenging at best. 70 Recent studies examining genetic risk factors for stroke found genetic predisposition to stroke to vary based on age and stroke subtype. 68, [71] [72] [73] A meta-analysis of genome-wide associations studies undertaken by the METASTROKE Collaboration confirmed that although genetic variants were detected in patients with ischemic stroke when compared to controls, all genetic variations were specific to a stroke subtype. 70 The METASTROKE Collaboration posited the implications of their findings were twofold: (1) to maximize success of genetic studies in ischemic stroke, detailed stroke subtyping is required; and (2) different genetic pathophysiological mechanisms appear to be associated with different stroke subtypes, possibly leading to pharmacotherapy having different effects in different stroke subtypes. Moving forward, detailed subtyping may be required to illustrate differing effect of pharmacological profiles in secondary stroke prevention. In addition, inherited single-gene disorders can also lead to abnormalities that predispose persons toward stroke, usually a specific sub type. For example, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) syndrome is associated with a mutation of the NOTCH3 gene, which manifests independently of traditional stroke risk factors. 74 The condition results in damage to small blood vessels, which reduces blood flow, leading to recurrent subcortical cerebral infarctions. Accordingly, stroke in younger persons should raise suspicion of the presence of one of these highly penetrant mutation, either established genes (e.g. CADASIL, Fabry) or emerging ones (e.g. COL4A2). These genetic abnormalities may be identified using next generation sequencing technology, in selected individuals.
Summary
The 2017 update of the Canadian Stroke Best Practice Secondary Prevention of Stroke Recommendations provides a common set of guiding principles for important aspects of secondary stroke prevention. The impact of secondary stroke prevention strategies is increased when individuals who have experienced a stroke or transient ischemic attack are able to access expert prevention care in a timely way. This requires coordinated systems to be in place in all regions to address the needs of individuals following an index event. In Canada, these systems have evolved over the past decade resulting in a growing number of stroke prevention services and protocols to increase access in many under-serviced areas. With emerging biomarkers and genetic information, the field of secondary prevention for stroke will continue to evolve. These recommendations are a work in progress and will continue to be regularly updated every 2-3 years in order to integrate newly released data in a timely way to help ensure optimal evidence-based patient care and outcomes.
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